Venosmine

Quick links to important sections

Venosmine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venosmine

Quick Facts: Venosmine (Diosmin)

Property Description
Active Ingredient Diosmin
Form Film-coated tablet (Oral administration)
Pharmacological Class Phlebotonic Agent / Venotonic Drug
General Purpose Support circulation in the veins and capillaries
Origin Semi-synthetic bioflavonoid derivative

Venosmine: Defining its Identity and Pharmacological Class

Venosmine is defined as a pharmaceutical product recognized as a phlebotonic agent and venotonic drug, characterizing its role in supporting the health and structural function of the venous system. This venoactive classification is associated with a beneficial effect on venous health.

Venosmine is specifically formulated for oral administration as a film-coated tablet, ensuring systemic action. The general purpose of this venotonic medication is to exert a beneficial effect on the dynamics of blood flow by enhancing venous tone and stabilizing capillaries.

Composition and Pharmaceutical Form: What is Diosmin?

The sole active ingredient in Venosmine is Diosmin, chemically classified as a bioflavonoid glycoside. Venosmine utilizes Diosmin prepared through a semi-synthetic process to achieve the high pharmaceutical purity required for medicine.

A critical distinguishing factor for this preparation is its use as a Micronized Purified Flavonoid Fraction (MPFF). This specialized micronization technology is designed to significantly enhance the absorption and bioavailability of the ingredient compared to non-micronized or simple bioflavonoid forms. This preparation's targeted action minimizes fluid leakage into tissues, supporting the medicine's role in reducing the stretching of veins and minimizing fluid leakage.

What side effects are possible with Venosmine?

Possible Side Effects and Safety Information for Venosmine

The safety profile for Venosmine (a product containing Diosmin) is generally considered favorable, with documented adverse reactions typically being minor and occurring rarely.

Adverse Reaction Summary

System-Organ Class Common (1 in 100 to 1 in 10 users) Rare (1 in 1,000 to 1 in 10,000 users)
Gastrointestinal Disorders Diarrhea, Dyspepsia (Indigestion), Nausea, Vomiting, Abdominal Pain Colitis
Nervous System Disorders Headaches Dizziness, Malaise
Skin and Subcutaneous Tissue Disorders Rash, Pruritus (Itching), Urticaria (Hives)

Serious or clinically significant reactions such as Quincke's edema (angioedema—rapid swelling that may cause breathing difficulty) have been reported at a frequency not known, warranting immediate medical attention if experienced. Overdose reports are limited, but are expected to primarily worsen the gastrointestinal side effects.

Contraindications and Safety Restrictions

This medication is formally contraindicated in patients with a known hypersensitivity or allergy to the active substance or any of the excipients.

Special Safety Considerations:

  • Pregnancy and Breastfeeding: Due to insufficient data, the use of Venosmine is generally not recommended or advised against during pregnancy and breastfeeding.
  • Hereditary Fructose Intolerance: Specific formulations, such as powder for oral suspension, may contain excipients that make the product contraindicated for patients with rare hereditary problems of fructose intolerance.
  • Drug Interactions: Venosmine may interact with other medications, including those that slow blood clotting (anticoagulants) or certain drugs metabolized by the liver (e.g., some anticonvulsants or anti-inflammatory drugs), potentially increasing the risk of adverse effects or altering drug effectiveness.

Overdose and Emergency Response

The regulatory overdose profile for Venosmine (Diosmin) is structured based on post-marketing reports of adverse events that have manifested following the ingestion of a dose exceeding the recommended amount. This information dictates the required help-seeking actions.

Documented Overdose Manifestations

The most frequently reported clinical manifestations detailed in the official regulatory prescribing information include specific symptoms affecting the Gastrointestinal System, such as diarrhoea, nausea, vomiting, and abdominal pain. Additionally, effects on the Skin have been documented, primarily including pruritus (itching) and rash. No severe, life-threatening, or systemic outcomes are explicitly detailed in the regulatory overdose sections.

Emergency Actions and Management

In the event of a suspected overdose, the official regulatory guidance is explicit regarding the need for immediate action. An individual must seek medical attention immediately or consult a doctor or pharmacist immediately if adverse symptoms are experienced after taking more than the prescribed dose. The documented management for Venosmine overdose is described as consisting of symptomatic treatment, which focuses on addressing the specific clinical signs that manifest. The official labeling notes that the existence of a specific pharmacological antidote is not detailed in the regulatory documentation.

Therapeutic Uses of Venosmine

Quick Facts

  • Chronic Venous Insufficiency: May offer symptomatic relief related to this condition.
  • Hemorrhoids: May support the management of symptoms associated with acute episodes.

Venosmine is a compound that may support the therapeutic management of certain venous disorders. Its primary use is in the context of chronic venous insufficiency (CVI), a condition where the veins have difficulty returning blood from the legs to the heart. In this therapeutic domain, the medication may help manage symptoms that include a sensation of leg heaviness, discomfort, pain, and other signs associated with poor venous circulation. This therapeutic application includes the potential for symptom improvement in the management of CVI.

Furthermore, Venosmine may also be used to provide symptomatic relief and support the management of acute hemorrhoidal episodes. This application focuses on easing the temporary discomfort and related signs of the condition.

When considering treatment for chronic venous disorders, patients should consult their healthcare professional to assess the appropriateness of this product for their specific condition.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Venosmine — official regulatory information

The following information details the official population eligibility and non-eligibility for Venosmine (Diosmin) as documented in regulatory sources.

Category Eligibility Rule (Official Regulatory Status)
Populations Allowed Adults (aged 18 years and older) are the established population for labeled use.
Contraindicated Populations Individuals with known Hypersensitivity to the active substance (Diosmin) or to any of the excipients.
Age-Related Eligibility Children and adolescents under 18 years of age: Safety and efficacy have not been established, and use is therefore not recommended.
Pregnancy Eligibility Pregnant women: Use is preferable to avoid as a precautionary measure, or only to be used if clearly necessary, due to limited human data.
Lactation Eligibility Breastfeeding women: Treatment is not recommended due to the absence of data on the passage of the substance into human milk.

Connection to the overall eligibility profile

The eligibility profile is structured by setting an absolute exclusion for individuals with hypersensitivity and explicitly identifying groups where safety data is insufficient. Regulatory documents classify the medicine as Contraindicated for allergic patients and Not Recommended or subject to conditional use for the pediatric population, and women who are pregnant or breastfeeding.

What should I know about interactions with other medicines?

Venosmine Interactions with other medicines and products

The official regulatory profile for Venosmine, which contains the active ingredient Diosmin, is characterized by a lack of reported adverse co-administration outcomes. Authoritative product labeling explicitly confirms that no specific interaction studies have been formally performed. Crucially, official product literature states that no clinically relevant drug interaction has been reported to date from global post-marketing experience.

Interaction Scope and Restrictions

This regulatory status means that the official documentation does not define or list any specific medicinal products or product categories that are contraindicated for co-administration with Venosmine. The labeling contains no formal warnings for pharmacokinetic mechanisms (such as CYP-enzyme effects) or pharmacodynamic interactions with other substances. Furthermore, no population-specific interaction considerations, such as heightened risk in patients with hepatic impairment, are described in the interaction sections of the official documents.

Timing-Based Co-administration Rule

The only official administration constraint related to substance intake is a timing-based requirement. Patient Information Leaflets (PI) from national health authorities mandate that Venosmine should be taken with meals or at mealtime. This rule is a formal condition of use outlined in the product labeling, not a classification of an adverse drug interaction.

Mechanism of Action

Venosmine operates via mechanisms that target three core biological pathways: vascular tone, endothelial integrity, and local inflammation. Its activity is dependent on the active metabolite, Diosmetin, which mediates the systemic pharmacodynamic processes.

Venous Wall Tone Modulation

This mechanism focuses on venous smooth muscle cells, enhancing their response to endogenous vasoconstrictors such as Noradrenaline. By functionally modulating the Ca^2+ (Calcium ion) sensitivity within these cells, the drug leads to a stronger, more sustained contraction, which results in increased venous tone and modulation of venous wall capacitance.

Capillary Barrier Stabilization

The drug acts on the microvascular endothelium to increase physical resistance and stabilize the capillary wall structure. This mechanistic domain reinforces the cell-to-cell junctions, modulating capillary hyperpermeability by reducing the rate of transcapillary fluid and macromolecule filtration into the interstitium.

Inhibition of Vascular Inflammation

Venosmine engages mechanisms that suppress the local inflammatory cascade by blocking the adhesion of leukocytes (neutrophils) to the vessel lining. This mechanism prevents the release of inflammatory enzymes and mediators, modulating the resultant structural changes in the vessel wall.

Dosage and Administration Information

How to Use Venosmine: Administration Guidelines

Administration of Venosmine (Diosmin/MPFF) follows established patterns that delineate high-level usage. This medication is administered via the oral route as a film-coated tablet. The usage pattern is differentiated based on the specific condition, utilizing either a long-term maintenance approach or a short-term intensive course.

Feature Guideline Summary
Route of Administration Oral route only, via film-coated tablet.
Timing in Relation to Meals Taken at meal times (with meals).
Age-Group Rules Safety and efficacy have not been established in individuals under 18 years of age.
Missed Dose Rule If a dose is missed, the next scheduled dose is taken at the usual time; the dose is not doubled to compensate.

Dosing Regimens and Course Duration

The required dose and frequency are determined by the targeted condition. For the long-term maintenance use associated with chronic conditions, the typical adult dose is 1000 mg total daily, often taken as two divided doses.

In contrast, the treatment of acute episodes involves a seven-day, short-term course utilizing a higher initial loading dose that is subsequently reduced. For the higher-dose acute regimen, the frequency temporarily increases to multiple times daily for the initial period before adjusting down. These parameters define the standardized procedural structure for the use of Venosmine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

The activity and safety profile of Venosmine (a flavonoid compound) in clinical trials focused on moderate-to-severe Chronic Venous Disease (CVD) have been the subject of several large-scale studies. These studies examined clinical endpoints over a 12-week period.

  • Primary Outcomes: Research examined whether the compound affected joint mobility in participants with active CVD. Secondary analysis investigated whether a change in pain and leg heaviness was reported, and the time-course of reported observations was studied.
  • Combination Therapy: Studies have explored the effects of combining Venosmine with physical therapy. Research has compared this treatment approach to other interventions, including standard compression therapy.
  • Duration of Observation: Researchers evaluated the duration of reduced inflammation in participants following the initial treatment phase.

Pharmacokinetics and Clinical Assessment

Clinical research has explored its hypothesized mechanism of action, which is generally categorized as a venoactive agent.

  • Assessment of Adverse Events: Research focused on the occurrence of adverse events in various populations, including close monitoring across different age groups. Special considerations were given to individuals with specific pre-existing conditions in clinical trials.
  • Pharmacokinetics: Studies investigated the pharmacokinetics (how the body processes the drug) and elimination pathway of Venosmine. Dosing schedules, including varied administration timings, have been a focus of clinical investigation.
  • Long-Term Research: The long-term observations of Venosmine on disease progression have been a focus of ongoing research, particularly related to the recurrence of symptoms.

Interpreting the Evidence

The compound has been the subject of several clinical trials. Due to the complexity of venous disorders, findings were mixed across specific patient subgroups, and further research is ongoing. It is important to discuss all treatment options with a healthcare provider to understand the available evidence and personal factors.

Frequently Asked Questions (FAQ)

Common questions about Venosmine (FAQ)

Q: What specific condition is Venosmine approved to treat?

According to official regulatory documents, Venosmine is approved for the symptomatic treatment of chronic venous insufficiency (CVI). It is also authorized, in some regimens, for the treatment of acute hemorrhoidal attacks, depending on the specific regulatory approval.


Q: Does Venosmine have a risk of dependence or addiction?

Official product labeling does not reference any risk of dependence or abuse associated with Venosmine. The medication is not classified as a controlled substance by regulatory agencies.


Q: Can Venosmine cause weight changes according to official documents?

Reports of weight gain or loss are not listed among the common or rare adverse drug reactions in the official regulatory product information. The safety profile does not include weight changes.


Q: Is there a list of common prescription drugs that interact with Venosmine?

The official product labeling states that no clinically relevant drug interactions have been reported to date from global post-marketing experience. Potential altered effects are noted with drugs that slow blood clotting (anticoagulants) or certain medications metabolized by the liver. Regulatory practice generally recommends informing a health professional of all medications being taken.


Q: Is it a myth that Venosmine is safe to stop taking once symptoms improve?

Official instructions define both a short-term intensive course for acute episodes and a long-term maintenance approach for chronic conditions. Regulatory documentation indicates that patients should follow the course duration prescribed and that stopping the medication prematurely is advised against.


Q: Does crushing or splitting the Venosmine tablet change its effectiveness?

Venosmine is supplied as a film-coated tablet. Regulatory guidance generally advises against splitting film-coated tablets unless an explicit score line is provided, as modification may potentially alter the drug’s stability or absorption rate.


Q: Does taking Venosmine at different times of the day reduce its benefit?

The official administration constraint is to take the tablets at meal times. The standard dosing regimen for long-term use often specifies divided doses throughout the day, which confirms that using the medicine at different times of the day is standard practice.


Q: Do clinical studies show that Venosmine helps with swelling specifically?

Clinical trial summaries and regulatory reviews have examined Venosmine’s effects on symptoms of Chronic Venous Disease. Studies have specifically reported effects on reducing signs such as leg and ankle swelling (edema) in patients.


Q: What exactly does 'treating chronic venous insufficiency' mean for patients?

The treatment of chronic venous insufficiency (CVI) with this medication is symptomatic, meaning the focus is on relieving discomfort. This involves improving symptoms associated with CVI, such as leg heaviness, pain, swelling, and functional discomfort.


Q: Do official sources define how Venosmine should affect my daily life?

While official sources do not define the drug’s overall effect on 'daily life,' clinical research often evaluates patient-reported outcomes (PROs). These studies measure changes in patient-relevant factors like pain, leg heaviness, and quality of life, which reflect the expected functional benefit.


Q: Are there restrictions on who can take Venosmine based on specific medical conditions?

Yes, official regulatory documents state that Venosmine is formally contraindicated (should not be used) if a patient has a known hypersensitivity or allergy to the active substance or any other ingredients. Additionally, some specific formulations are contraindicated for patients with hereditary fructose intolerance.


Q: How long does it typically take for Venosmine to start showing effects?

Studies and official information indicate that improvements in common symptoms like pain and heaviness can be observed within the first month of treatment. Observations suggest that the full benefit may be associated with longer, continuous use, aligned with maintenance regimens.


Q: Is Venosmine safe for older adults or elderly populations?

Clinical trials for this medication included older patient populations. However, no specific warnings or dose adjustments based solely on age are typically listed in the official product labeling for the elderly population.


Q: Can I take Venosmine with over-the-counter pain relievers like ibuprofen or acetaminophen?

Official documentation reports that no clinically relevant drug interaction has been observed with common over-the-counter pain relievers. Official safety practice recommends informing a healthcare professional of all medications being taken, including OTC products.


Q: Does alcohol interact with Venosmine?

The official product labeling and regulatory safety reviews do not list a formal warning or contraindication regarding the consumption of alcohol while taking Venosmine.


Q: Is it safe to use herbal supplements, such as St. John's Wort, while taking Venosmine?

Official product labeling does not list specific interactions with common herbal supplements. The importance of informing a healthcare professional of all supplements being taken is noted, as some supplements have the potential to interact with medications metabolized by the liver.

How should Venosmine be stored and disposed of?

The storage and disposal of Venosmine tablets must strictly follow the conditions specified in the official regulatory labeling.

Storage Requirements

The product must be stored at temperatures not exceeding 30 C and must be kept in the original outer packaging. Stability is maintained until the labeled expiry date, and the tablets must not be used after this date.

Child Safety and Disposal

It is a mandatory safety requirement that the medicine be kept out of the sight and reach of children.

Disposal must adhere to environmental regulations: Venosmine should not be disposed of via wastewater or household waste. The official instruction is to ask a pharmacist how to correctly dispose of any unused or expired product to ensure proper waste handling and environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venosmine found in:

A-Z Index: